April 11, 2011 -- Dr Glynis Neagle, Synexus’ Chief Medical Officer will be discussing the challenges facing global vaccine trials at the World Vaccine Congress in Washington this week.
In her presentation to delegates Dr Neagle will be using the company’s considerable experience to examine the benefits and risks of conducting vaccine trials in the developed and developing worlds and looking at how best to manage vaccine trials that involve working with multiple organisations.
Commenting on her involvement with this year’s World Vaccine Congress Dr Neagle said: “This event represents a great opportunity for industry and scientific leaders to share their thoughts, ideas and experience of the development of new vaccines. Successful clinical trials are critical to the safe and speedy development of all vaccines and depending upon the therapeutic indication, trials may be run in many diverse locations. I will be discussing some of the challenges of conducting clinical trials under these circumstances, and the solutions Synexus has devised to deliver successful late stage vaccine trials. I will also be looking at the challenges of working with multiple organisations in different countries, diverse populations, access to healthcare facilities and the logistics of clinical trial samples.”
Synexus has recently created a specialist vaccines team to help pharma and biotech companies find the thousands of patients they need for their late phase vaccine trials. The company has a well-established reputation for delivering results in the vaccine field following successes in late phase vaccine trials including most recently, studies for cancer prevention, influenza and rotavirus, where it has delivered in excess of three thousand randomised patients in all three areas. It has also been involved in a number of paediatric vaccine trials, with particular success in South Africa.
The annual World Vaccine Conference, which attracted over 485 delegates in 2010, provides attendees with the opportunity to hear from North America’s leading governmental stakeholders, business leaders and scientific stakeholders as they continue to enhance the scientific and strategic innovation behind a burgeoning vaccine industry. For more information about the conference, visit: www.terrapinn.com/conference/world-vaccine-congress-washington/index.stm.
Synexus notes:
Synexus® headquartered in Manchester, England, is the world’s largest multi-national company dedicated to the recruitment and running of clinical trials at its own research centres across the globe on behalf of its pharmaceutical, biotech and CRO clients. Synexus now has 26 Dedicated Research Centres across the UK, Germany, Austria, Poland, Hungary, Ukraine, Bulgaria, India and South Africa staffed by full-time GCP-trained investigators.
The traditional way of recruiting for clinical trials through individual doctors is still by far the most common method, despite the fact that each doctor only recruits an average of five patients per study and more than 60 percent recruit one or less. This incredibly costly model remains the norm.
Dr Glynis Neagle, Chief Medical Officer
Dr Neagle has worked as a pharmaceutical industry physician for over 12 years and has extensive experience in the clinical trials sector including large global registration trials and post-marketing studies. Her areas of therapeutic expertise include oncology, internal medicine and sleep studies. Dr Neagle joined Synexus from Norgine Ltd, a specialist GI/Hepatology pharmaceutical company, where she was Director of Clinical Development. She previously spent several years working for Covance where she was latterly VP of Medical Affairs.
Sandra Hobson
Vane Percy & Roberts
Robert Denholm House
Bletchingley Road
Nutfield
Surrey
RH1 4HW
(Office) + 44 (0) 1737 821891
(Mobile) + 44 (0) 7900 828618
(Fax) + 44 (0) 1737 821899
www.vanepercy.com
